Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report.

ABSTRACT: Warm autoimmune hemolytic anemia (AIHA) is a hematologic disorder with an incidence of 1-3 per 10⁵ individuals/year. Patients with systemic lupus erythematosus (SLE) develop AIHA in 3% of adult cases and 14% of pediatric cases. We report a case of AIHA refractory to multiple lines of treatment in a patient with SLE, who eventually responded to a proteasome inhibitor-based combination. A patient with systemic lupus erythematous was diagnosed with symptomatic autoimmune hemolytic anemia. The patient was refractory to multiple lines of treatment including prednisone, intravenous immune globulin, methylprednisolone, rituximab, cyclophosphamide, mycophenolate mofetil, and splenectomy. She eventually had a beneficial response to a proteasome inhibitor-based combination with bortezomib

SUBMITTER: Crawford LR 

PROVIDER: S-EPMC8933632 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature